文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

贝利尤单抗治疗狼疮性肾炎的两年随机对照试验

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
PubMed 文献 · N Engl J Med · 2020-01-01

这项3期多国随机双盲安慰剂对照试验纳入448例活动性狼疮性肾炎成人患者,在标准治疗基础上加用静脉贝利尤单抗10 mg/kg或安慰剂。第104周时,贝利尤单抗组主要疗效肾脏应答率和完全肾脏应答率均显著高于安慰剂组,肾脏相关事件或死亡风险更低,安全性与此前试验一致。

要点

  • 贝利尤单抗组第104周主要疗效肾脏应答率为43%,安慰剂组为32%。
  • 贝利尤单抗组完全肾脏应答率为30%,安慰剂组为20%。
  • 贝利尤单抗组肾脏相关事件或死亡风险更低,风险比为0.51。

核心结论

  • 在活动性狼疮性肾炎患者中,贝利尤单抗联合标准治疗较单用标准治疗有更多患者达到主要疗效肾脏应答。

研究设计与样本

  • 3期、多国、多中心、随机、双盲、安慰剂对照、104周试验。
  • 在21个国家107个中心进行,448例活检证实的活动性狼疮性肾炎成人按1:1随机分组。
  • 贝利尤单抗组224例接受静脉贝利尤单抗10 mg/kg,安慰剂组224例接受匹配安慰剂,均联合标准治疗。

主要发现

  • 第104周主要疗效肾脏应答率贝利尤单抗组43% vs 安慰剂组32%,比值比1.6(95%CI 1.0–2.3),P=0.03。
  • 第104周完全肾脏应答率贝利尤单抗组30% vs 安慰剂组20%,比值比1.7(95%CI 1.1–2.7),P=0.02。
  • 肾脏相关事件或死亡风险贝利尤单抗组低于安慰剂组,风险比0.51(95%CI 0.34–0.77),P=0.001。
  • 贝利尤单抗的安全性特征与此前试验一致。

关键数值与推荐

  • 主要疗效肾脏应答定义:尿蛋白/肌酐比值≤0.7,eGFR不低于肾脏 flares 前值的20%或≥60 ml/min/1.73 m²,且未使用挽救治疗。
  • 完全肾脏应答定义:尿蛋白/肌酐比值<0.5,eGFR不低于 flare 前值的10%或≥90 ml/min/1.73 m²,且未使用挽救治疗。
  • 主要终点为第104周的主要疗效肾脏应答,主要次要终点为完全肾脏应答。

临床怎么用

  • 对于活动性狼疮性肾炎成人,可考虑在标准治疗基础上加用静脉贝利尤单抗10 mg/kg以改善肾脏应答。
  • 治疗决策需结合患者个体情况,并关注肾脏相关事件或死亡风险的降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: In a phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 104-week trial conducted at 107 sites in 21 countries, we assigned adults with biopsy-proven, active lupus nephritis in a 1:1 ratio to receive intravenous belimumab (at a dose of 10 mg per kilogram of body weight) or matching placebo, in addition to standard therapy. The primary end point at week 104 was a primary efficacy renal response (a ratio of urinary protein to creatinine of ≤0.7, an estimated glomerular filtration rate [eGFR] that was no worse than 20% below the value before the renal flare (pre-flare value) or ≥60 ml per minute per 1.73 m2 of body-surface area, and no use of rescue therapy), and the major secondary end point was a complete renal response (a ratio of urinary protein to creatinine of <0.5, an eGFR that was no worse than 10% below the pre-flare value or ≥90 ml per minute per 1.73 m2, and no use of rescue therapy). The time to a renal-related event or death was assessed. RESULTS: A total of 448 patients underwent randomization (224 to the belimumab group and 224 to the placebo group). At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6; 95% confidence interval [CI], 1.0 to 2.3; P = 0.03) and a complete renal response (30% vs. 20%; odds ratio, 1.7; 95% CI, 1.1 to 2.7; P = 0.02). The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51; 95% CI, 0.34 to 0.77; P = 0.001). The safety profile of belimumab was consistent with that in previous trials. CONCLUSIONS: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. (Funded by GlaxoSmithKline; BLISS-LN ClinicalTrials.gov number, NCT01639339.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020. PMID: 32937045. doi:10.1056/NEJMoa2001180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。